Migraine is a common and often disabling neurologic disorder characterized by recurrent headaches accompanied by photophobia, phonophobia, nausea, and, in some cases, aura. Advances in migraine treatment have shifted care toward mechanism-based therapies targeting
calcitonin gene-related peptide (CGRP):
- CGRP monoclonal antibodies for prevention (erenumab, fremanezumab,
galcanezumab, eptinezumab) - Gepants for acute and preventive treatment
- Ditans for acute migraine management
These therapies have significantly improved outcomes for patients with refractory or chronic migraine.